Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2023, Volume and Issue: 397(5), P. 2793 - 2833

Published: Nov. 22, 2023

Language: Английский

---

Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(5), P. 648 - 648

Published: May 11, 2024

Inhaled ciprofloxacin (CFX) has been investigated as a treatment for lower respiratory tract infections (LRTIs) associated with cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and bronchiectasis. The challenges in CFX effectiveness LRTI include poor aqueous solubility therapy resistance. dry powder inhalation (DPI) formulations were well-tolerated, showing remarkable decline overall bacterial burden compared to placebo bronchiectasis patients. Recent research using an inhalable combining Pseudomonas phage PEV20 exhibited substantial reduction density mouse lungs infected clinical P. aeruginosa strains reduced inflammation. Currently, studies suggest that elevated biosynthesis of fatty acids could serve potential biomarker detecting resistance LRTIs. Furthermore, inhaled successfully addressed various traditional CFX, including the incapacity eliminate pathogen, recurrence colonization, development However, further exploration is needed address three key unresolved issues: identifying right patient group, determining optimal duration, accurately assessing risk antibiotic resistance, additional multicenter randomized controlled trials suggested tackle these challenges. Importantly, future investigations will focus on DPI COPD, aiming differentiate prognoses between two conditions. This review underscores importance against LRTIs preclinical sectors, their challenges, recent advancements, perspectives.

Language: Английский

---

Antibiotic loaded inhalable liposomal nanoparticles against lower respiratory tract infections: Challenges, recent advances, and future perspectives

Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 94, P. 105517 - 105517

Published: Feb. 28, 2024

Lower respiratory tract infections (LRTIs) are inherited disorders which often causes chronic for patients repeatedly receive oral antibiotics, particularly during periods of worsened lung symptoms. However, the existing treatment modalities unable to completely clear responsible pathogens, contributes emergence antimicrobial resistance (AMR). To circumvent these issues, direct delivery antibiotics infected cells by inhalation is emerging as a preferred strategy. More importantly, antibiotic-loaded inhalable liposomal nanoparticles (ALILNPs) an attractive option efficient management LRTIs such cystic fibrosis (CF), obstructive pulmonary disease (COPD), and bronchiectasis. ALILNPs have demonstrated significantly higher antibacterial efficacy in both preclinical clinical settings. Furthermore, several studies reported that inhaled show sustained enhancements function amelioration forced expiratory volume 1 s (FEV1) depletion P. aeruginosa density. Liposome considered safe administering range improve remedial effectiveness incorporated agents diminish drug toxicity. Toxicity aspects liposomes are, however, still not abundantly reported. Thus, there exists compelling requirement development vitro or vivo models gain insights into safety within system. Although, impact on macrophages biofilms arising from well established, full potential formulations yet be realised. Herein, we discuss challenges, recent advances, future perspectives various pathogens associated with LRTIs.

Language: Английский

---

Natural deep eutectic solvents (NADES) in drug delivery systems: Characteristics, applications, and future perspectives

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125509 - 125509

Published: March 1, 2025

Language: Английский

---

Advances in lipid-based nanoformulations for inhaled antibiotic therapy in respiratory infections

Drug Discovery Today, Journal Year: 2025, Volume and Issue: unknown, P. 104380 - 104380

Published: May 1, 2025

Language: Английский

---

Inflammatory-Targeted Lipid Carrier as a New Nanomaterial to Formulate an Inhaled Drug Delivery System

Molecules, Journal Year: 2024, Volume and Issue: 29(7), P. 1616 - 1616

Published: April 3, 2024

There is a pressing need for efficacious therapies in the field of respiratory diseases and infections. Lipid nanocarriers, administered through aerosols, represent promising tool maximizing therapeutic concentration targeted cells minimizing systemic exposure. However, this approach requires application efficient safe nanomaterials. Palmitoylethanolamide (PEA), an endocannabinoid-like endogenous lipid, plays crucial role providing protective mechanisms during inflammation, making it interesting material preparing inhalable lipid nanoparticles (LNPs). This report aims to preliminarily explore vitro behavior LNPs prepared with PEA (PEA-LNPs), new inflammatory-targeted nanoparticulate drug carrier. PEA-LNPs exhibited size about 250 nm, rounded shape, marked improvement solubility comparison naked PEA, indicative easily disassembled nanoparticles. A twin glass impinger instrument was used screen aerosol performance PEA-LNP powders, obtained via freeze-drying presence two quantities mannose as cryoprotectant. Results indicated that higher amount improved emitted dose (ED), particular, fine particle fraction (FPF). cytotoxicity assay performed are not toxic towards MH-S alveolar macrophage cell line up concentrations 0.64 mg/mL, using coumarin-6 labelled particles, rapid internalization into confirmed. study demonstrates could suitable nanocarrier-based dry which signify transport drugs employed treat

Language: Английский

---

Precise antibiotic delivery to the lung infection microenvironment boosts the treatment of pneumonia with decreased gut dysbiosis

Acta Biomaterialia, Journal Year: 2024, Volume and Issue: 184, P. 352 - 367

Published: June 21, 2024

Language: Английский

---

Exploring Bioactive Phytomedicines for Advancing Pulmonary Infection Management: Insights and Future Prospects

Phytotherapy Research, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 9, 2024

Pulmonary infections have a profound influence on global mortality rates. Medicinal plants offer promising approach to address this challenge, providing nontoxic alternatives with higher levels of public acceptance and compliance, particularly in regions where access conventional medications or diagnostic resources may be limited. Understanding the pathophysiology viruses bacteria enables researchers identify biomarkers essential for triggering diseases. This knowledge allows discovery biological molecules capable either preventing alleviating symptoms associated these infections. In review, medicinal that an effect COVID-19, influenza A, bacterial viral pneumonia, tuberculosis are discussed. Drug delivery has been briefly discussed as well. It examines bioactive constituents synthesizes findings from vitro, vivo, clinical studies conducted over past decade. conclusion, many can used treat pulmonary infections, but further in-depth needed most current only at preliminary stages. Extensive investigation warranted fully elucidate their mechanisms action optimize use practice.

Language: Английский

---

Translational hurdles in anti-asthmatic nanomedicine development

Expert Opinion on Drug Delivery, Journal Year: 2024, Volume and Issue: 21(7), P. 987 - 989

Published: July 2, 2024

Language: Английский

---

Therapeutic Potential of 18-β-Glycyrrhetinic Acid-loaded Poly (lactic-co-glycolic acid) Nanoparticles on Cigarette Smoke-Induced in-vitro model of COPD

Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 263, P. 155629 - 155629

Published: Sept. 28, 2024

Language: Английский

---